

# Jim Dimitroulakos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4848290/jim-dimitroulakos-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

896  
citations

18  
h-index

25  
g-index

25  
ext. papers

980  
ext. citations

8.8  
avg, IF

3.56  
L-index

#	Paper	IF	Citations
24	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
23	Rationally Designed 3D Hydrogels Model Invasive Lung Diseases Enabling High-Content Drug Screening. <i>Advanced Materials</i> , <b>2019</b> , 31, e1806214	24	32
22	Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. <i>Molecular Oncology</i> , <b>2018</b> , 12, 423-440	7.9	39
21	Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2018</b> , 40, 1697-1706	4.2	14
20	Co-inhibition of mTORC1, HDAC and ESR1 retards the growth of triple-negative breast cancer and suppresses cancer stem cells. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 815	9.8	27
19	Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , <b>2018</b> , 47, 74	5.4	2
18	HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , <b>2017</b> , 46, 3	5.4	19
17	Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4501-4510	12.9	30
16	Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER $\alpha$ inhibition. <i>FEBS Letters</i> , <b>2016</b> , 590, 4606-4616	3.8	23
15	Assessment of Circulating LncRNAs Under Physiologic and Pathologic Conditions in Humans Reveals Potential Limitations as Biomarkers. <i>Scientific Reports</i> , <b>2016</b> , 6, 36596	4.9	43
14	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 83	8.5	14
13	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150567	3.7	27
12	Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells. <i>Neoplasia</i> , <b>2016</b> , 18, 525-35	6.4	19
11	miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, e121-9	4.9	20
10	Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2559-71	6.1	18
9	Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8048-8048	2.2	1
8	Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4426s-4431s	12.9	44

7	A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 523-30	7.5	80
6	Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 2398-407	12.9	80
5	Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2003</b> , 129, 631-41	4.9	28
4	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. <i>Blood</i> , <b>1999</b> , 93, 1308-1318	2.2	174
3	Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. <i>Journal of Neuro-Oncology</i> , <b>1999</b> , 42, 1-11	4.8	60
2	Identification of a novel zinc finger gene, zf5-3, as a potential mediator of neuroblastoma differentiation. <i>International Journal of Cancer</i> , <b>1999</b> , 81, 970-8	7.5	8
1	HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. <i>Nature Medicine</i> , <b>1996</b> , 2, 326-33	50.5	92